US 12,404,341 B2
Glypican-3 (GPC-3) antibodies
Cheng-I Wang, Singapore (SG); Bei Wang, Singapore (SG); Zi Xian Eve Ngoh, Singapore (SG); Wen-Hsin Lee, Singapore (SG); Ching-Wen Huang, Singapore (SG); and Yee Chin Yvonne Yeap, Singapore (SG)
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Connexis (SG)
Appl. No. 17/441,519
Filed by AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Connexis (SG)
PCT Filed Mar. 22, 2020, PCT No. PCT/SG2020/050152
§ 371(c)(1), (2) Date Sep. 21, 2021,
PCT Pub. No. WO2020/190217, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 10201902550P (SG), filed on Mar. 21, 2019.
Prior Publication US 2022/0162335 A1, May 26, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/303 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 24 Claims
 
1. An antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) sequence and a light chain variable region (VL) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 and which specifically binds to glypican-3 (GPC-3).